Cyrus Biotechnology Appoints Jake Litwicki as VP of Engineering

Cyrus growing its team to speed biologics and small molecule
drug development software to market

SEATTLE, WA August 6, 2018 — Cyrus Biotechnology, a biotechnology software company
offering first-in-class tools for advanced protein modeling and discovery in drug development,
announced today the appointment of Jake Litwicki as VP of Engineering. Jake will lead software
engineering for the Cyrus Bench Software as a Service platform which speeds development of
new drugs and products sold to client firms in pharmaceuticals, biotechnology therapeutics,
synthetic biology and consumer products. Jake’s team will continue to grow the Cyrus Bench
toolkit, and add valuable new features including tools for antibody and biologics discovery as
well as small molecule modeling and discovery.  Prior to joining Cyrus Jake led software
engineering teams and spearheaded the transition to more modern cloud architectures at a
custom software development firm, a marketing technology startup, and most recently as the
leader of the Platform, Global and Microservice teams at Sterling Talent Solutions.
“Jake is a seasoned technical leader with experience across a variety of company and team
sizes, with a proven ability to bring widely used software to the market and to drive
improvement and best practices in an engineering organization,” said Dr. Lucas Nivon, CEO of
Cyrus. “Jake’s passion for software engineering, architecture and leadership will make him an
important part of our growth as we add scientific users at companies worldwide.”
“Cyrus is a unique organization with the potential to literally change the world for the better.
Having the opportunity to contribute to something with that kind of impact is truly inspiring”,
said Jake.  “I am eager to help grow and evolve the Cyrus team into a world leader in both
biotechnology and software as a service”, he added.

Jake’s team at Cyrus will be responsible for software frontend, backend, testing and release of
new scientific features developed by the open source RosettaCommons community, by other
Cyrus partners, or by Cyrus’s scientific software development and infrastructure team. Cyrus
software and services are currently being utilized by multiple companies including 10 of the top
20 Global Pharmaceutical firms, not only to design new drugs but also to offer solutions for
problems in drugs already under development.

Cyrus Biotechnology, Inc. is a privately-held biotechnology software company offering protein
modeling and design capabilities to the Biotechnology, Pharmaceutical, Chemical, Consumer
Products and Synthetic Biology industries. Cyrus was founded in 2014 as a spin-out from the
University of Washington, and offers Cyrus Bench®, a Software-as-a-Service (SaaS) platform for
protein structure prediction, modeling, stabilization, engineering and design to accelerate
discovery of Biologics and Small Molecules. Cyrus Bench is based primarily on the Rosetta
software package from Prof. David Baker’s lab at the University of Washington, along with
associated software. Cyrus Bench offers the world-leading protein structure prediction pipeline
of Rosetta and SparksX, the top structure prediction software in the bi-annual CASP
competition and the weekly CAMEO competition, as well as the only protein engineering
software experimentally proven to design new proteins completely via software.. Cyrus in
financed by leading investors in both Technology and Biotechnology, including Trinity Ventures,
Orbimed, Springrock Ventures, Alexandria Venture Investments, the W Fund, and others.